Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2016
|
| gptkbp:ATCCode |
J05AF13
|
| gptkbp:CASNumber |
379270-37-8
|
| gptkbp:chemicalFormula |
C21H29O5N6P
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to tenofovir alafenamide |
| gptkbp:drugClass |
antiviral
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:tenofovir_alafenamide
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vemlidy
|
| gptkbp:indication |
treatment of hepatitis B virus infection in adults
treatment of hepatitis B virus infection in adolescents |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:mechanismOfAction |
nucleotide reverse transcriptase inhibitor
|
| gptkbp:pregnancyCategory |
Not assigned (US)
B1 (Australia) |
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
abdominal pain fatigue headache cough |
| gptkbp:usedFor |
chronic hepatitis B
|
| gptkbp:bfsParent |
gptkb:tenofovir_alafenamide
|
| gptkbp:bfsLayer |
7
|